List of Excipients in Branded Drug TENORMIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Upsher-Smith Laboratories LLC	TENORMIN	atenolol	24979-244	CELLULOSE, MICROCRYSTALLINE
Upsher-Smith Laboratories LLC	TENORMIN	atenolol	24979-244	MAGNESIUM STEARATE
Upsher-Smith Laboratories LLC	TENORMIN	atenolol	24979-244	POVIDONE
Upsher-Smith Laboratories LLC	TENORMIN	atenolol	24979-244	SODIUM STARCH GLYCOLATE TYPE A POTATO

Generic Drugs Containing TENORMIN

Company	Ingredient	NDC	Excipient
Northwind Pharmaceuticals	atenolol	51655-929	CELLULOSE, MICROCRYSTALLINE
Northwind Pharmaceuticals	atenolol	51655-929	MAGNESIUM STEARATE
Northwind Pharmaceuticals	atenolol	51655-929	POVIDONE K30
Northwind Pharmaceuticals	atenolol	51655-929	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in TENORMIN?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	MAGNESIUM STEARATE
1	POVIDONE K30
1	SODIUM STARCH GLYCOLATE TYPE A POTATO

Tenormin Excipient Strategy and Commercial Opportunities for Atenolol

Last updated: September 9, 2026

Tenormin is the branded formulation of atenolol, a beta-1 selective adrenergic blocker used primarily for hypertension, angina pectoris, and selected cardiovascular indications. Its core US market protection has expired, and generic atenolol products dominate supply. Commercial opportunity therefore depends on formulation differentiation, excipient optimization, alternate dosage forms, adherence improvement, and market-specific regulatory positioning rather than on conventional small-molecule patent exclusivity.

The most attractive opportunities are low-cost, stable oral products that improve swallowing, dosing flexibility, pediatric or geriatric usability, and supply reliability. A new atenolol product would face limited active-ingredient IP barriers but would need to establish bioequivalence, control dissolution behavior, and avoid formulation changes that alter exposure or renal clearance.

What is Tenormin and which active ingredient does it contain?

Tenormin contains atenolol, a hydrophilic, beta-1 selective beta blocker. The branded product was developed by ICI and later commercialized by AstraZeneca. US labeling identifies tablets in 25 mg, 50 mg, and 100 mg strengths.[1]

Attribute	Tenormin
Active ingredient	Atenolol
Drug class	Beta-1 selective adrenergic blocker
Primary indications	Hypertension and angina pectoris
Common strengths	25 mg, 50 mg, 100 mg
Original dosage form	Immediate-release oral tablet
US reference product	Tenormin tablets
US approval	NDA 018544
Current market structure	Generic-dominated
Primary elimination	Renal excretion
Key formulation concern	Consistent dissolution and bioavailability

Atenolol has relatively low lipid solubility and limited penetration into the central nervous system compared with more lipophilic beta blockers. Renal function has a material effect on exposure, which creates a formulation and labeling issue for patients with impaired kidney function.[1]

What excipients are used in Tenormin tablets?

The US Tenormin label identifies inactive ingredients including corn starch, gelatin, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, and sodium starch glycolate.[1] Exact excipient composition can vary by market, manufacturing site, and historical product presentation. Commercial developers should use the current reference-product labeling and product samples for definitive comparative work.

Excipient	Likely formulation function	Commercial relevance
Corn starch	Filler and disintegrant	Low-cost, established oral-solid excipient
Gelatin	Binder or processing aid	Animal-origin and labeling considerations
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturability
Magnesium stearate	Lubricant	Excessive use can slow wetting and dissolution
Povidone	Binder	Controls granule strength and tablet integrity
Sodium lauryl sulfate	Wetting agent	May improve wetting of hydrophilic or poorly dispersing powders
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet breakup

The excipient system is conventional and technically reproducible. It does not create a meaningful standalone barrier to generic competition. Its commercial value lies in process performance, dissolution consistency, tablet robustness, and the ability to support an efficient ANDA or other national generic filing.

How strong is the Tenormin patent estate?

The Tenormin patent estate is commercially weak because the original composition and product exclusivity periods expired decades ago. Atenolol is an established small molecule, and generic manufacturers have long marketed immediate-release tablets.

The principal protection once associated with Tenormin was based on the atenolol active ingredient and its pharmaceutical use. Those rights do not provide a current barrier to ordinary atenolol tablets. The FDA Orange Book is the controlling reference for current US patent and exclusivity listings associated with approved reference products.[2]

Protection category	Current commercial position
Active-ingredient patent	Expired
Original formulation protection	Expired or commercially immaterial
New chemical entity exclusivity	Expired
Current Orange Book barrier	No meaningful barrier for standard atenolol tablets
Formulation opportunity	Available through new dosage forms and excipient systems
Method-of-use opportunity	Limited by mature clinical use and generic substitution

A new formulation could receive patent protection if it contains a genuinely novel and non-obvious excipient system, release profile, dosage form, or manufacturing process. A simple substitution of one conventional filler for another would face a weak patentability position.

When did Tenormin lose exclusivity?

Tenormin lost practical US market exclusivity after the expiration of the original atenolol patent and the entry of generic products. The product’s approval predates the modern Hatch-Waxman framework, and the current commercial market is not protected by an active brand patent estate.

The exact patent history should be separated from current Orange Book status. Historical compound patents may appear in USPTO or litigation records without creating a current launch barrier. For commercial planning, the relevant facts are that:

1. Generic atenolol tablets are widely approved.
2. Standard 25 mg, 50 mg, and 100 mg immediate-release products are established.
3. No new chemical entity exclusivity remains.
4. A new applicant can pursue a generic or differentiated product without licensing Tenormin’s original sponsor.

What is the Orange Book status of Tenormin?

The Orange Book identifies approved reference products, therapeutic-equivalence information, patents, and exclusivity data for FDA-approved drugs.[2] Tenormin’s commercial relevance today is primarily as the reference product for atenolol tablets, not as a product with active market exclusivity.

Generic applicants should distinguish between:

• The reference listed drug, or RLD.
• An approved generic with an “AB” therapeutic-equivalence rating.
• A discontinued or withdrawn brand presentation.
• Any remaining patent listing tied to a particular NDA.
• Product-specific labeling differences, including inactive ingredients.

The absence of an active patent barrier does not eliminate regulatory requirements. An ANDA applicant still must demonstrate pharmaceutical equivalence and bioequivalence, manufacture under current good manufacturing practice, and address labeling and impurity controls.[3]

What excipient strategy is most attractive for a new atenolol product?

The strongest strategy is a controlled, low-risk excipient platform that preserves immediate release while improving manufacturability, patient acceptability, or supply-chain flexibility.

1. Lactose-free and allergen-conscious tablets

A lactose-free formulation can serve patients and institutions that prefer to avoid lactose or animal-derived gelatin. The reference formulation’s use of gelatin creates an opportunity to develop a plant-based or synthetic alternative, although the commercial benefit must be validated because the tablet dose is small and generic competition is price-sensitive.

Potential excipient approaches include:

• Microcrystalline cellulose or dibasic calcium phosphate as primary diluent.
• Povidone or hydroxypropyl cellulose as binder.
• Crospovidone or croscarmellose sodium as alternative disintegrant.
• Vegetable-derived magnesium stearate or alternative lubricant.
• Removal of gelatin from the formulation and manufacturing process.

The main risk is that changing the diluent and disintegrant can affect hardness, friability, disintegration, and dissolution.

2. Low-sodium and renal-care positioning

Atenolol is frequently used in patients with cardiovascular disease, including patients with renal impairment. A low-sodium formulation may have institutional or diet-related appeal, but the commercial claim must be precise. Most tablet excipients contribute little sodium unless sodium-containing excipients are used in substantial quantities.

Developers should avoid sodium-based excipients where technically practical if the product is intended for strict low-sodium procurement programs. The product would still require careful nutritional and elemental analysis before making a low-sodium claim.

3. Orally disintegrating tablets

An orally disintegrating atenolol tablet could target older adults, patients with dysphagia, home-care settings, and emergency medication administration. The opportunity is technically credible because the atenolol dose is modest and the drug is water soluble enough to support rapid dispersion.

Candidate excipients include:

• Mannitol for mouthfeel and bulk.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Low-substituted hydroxypropyl cellulose for tablet breakup.
• Aspartame, sucralose, or non-sugar sweeteners for palatability.
• Flavor systems compatible with atenolol’s taste profile.

The principal barriers are taste masking, mechanical fragility, moisture sensitivity, packaging, and bioequivalence. A product that dissolves in the mouth but is swallowed before complete absorption may still require conventional systemic bioequivalence testing.

4. Oral liquid or powder-for-reconstitution

Atenolol oral liquid could address pediatric use, feeding-tube administration, patients unable to swallow tablets, and individualized dosing for renal impairment. The formulation would need a validated preservative system, pH control, microbial protection, and chemical stability.

Potential commercial formats include:

• Ready-to-use oral solution.
• Concentrated solution for pharmacy dispensing.
• Powder for reconstitution.
• Unit-dose cups or oral syringes.
• Tube-compatible suspension or solution.

Atenolol’s renal elimination makes flexible dosing commercially relevant, but the product must avoid dosing errors. An oral liquid could also face competition from pharmacy-compounded preparations, which may reduce pricing power.

5. Scored and flexible-dose tablets

A scored 25 mg, 50 mg, or 100 mg tablet could support dose titration, especially where the prescribing market uses half-tablet dosing. Scoring must be supported by tablet uniformity, breaking-force, stability, and dose-content data.

This is a low-complexity opportunity with limited patent strength. Its value would come from procurement convenience, not exclusivity.

What formulation patents could protect a new atenolol product?

Atenolol itself is no longer an attractive source of broad patent protection. New protection would need to focus on a specific technical result that is difficult to obtain using routine formulation methods.

Potential claim areas include:

Patent area	Potential claim subject	Relative strength
Orally disintegrating tablet	Defined excipient ratios and disintegration time	Moderate if data show unexpected performance
Taste masking	Coated particles, ion-pairing, or multiparticulate system	Moderate to strong if technically distinctive
Modified release	Polymer matrix or multiparticulate release profile	Moderate, but limited clinical need
Liquid formulation	Stable preservative and pH system	Weak to moderate unless stability is unexpected
Tube administration	Low-clogging, dispersible dosage form	Moderate if supported by functional data
Manufacturing process	Granulation, lubrication, or compression sequence	Moderate if it improves dissolution or yield
Combination product	Atenolol with another active ingredient	Dependent on combination clinical and formulation claims

The strongest formulation filing would combine composition claims with functional data. Examples include a defined disintegration window, dissolution profile, moisture stability, taste-masking performance, or improved content uniformity. Broad claims covering conventional excipient substitutions are unlikely to withstand serious validity scrutiny.

What generic entry risks exist for a new Tenormin formulation?

Generic entry risk is high for conventional atenolol tablets and lower for technically differentiated dosage forms. The distinction is important because a new product that uses an ordinary tablet platform may have no meaningful commercial protection even if it obtains approval.

Product concept	Generic substitution risk	Differentiation potential
Conventional 25 mg tablet	Very high	Low
Conventional 50 mg tablet	Very high	Low
Conventional 100 mg tablet	Very high	Low
Scored tablet	High	Low to moderate
Orally disintegrating tablet	Moderate	Moderate
Ready-to-use oral solution	Moderate	Moderate
Pediatric liquid with dosing device	Moderate	Moderate to high
Taste-masked multiparticulate	Lower initially	High if clinically useful
Modified-release product	Lower initially	High, but development cost is higher
Combination product	Depends on partner drug	Moderate to high

A Paragraph IV challenge would be relevant only if a new innovator formulation obtained listed patents. For the legacy Tenormin immediate-release tablet, the commercial market already reflects generic entry. Any new patent estate covering an improved formulation could attract Paragraph IV litigation once an ANDA applicant certifies that the listed patents are invalid, unenforceable, or not infringed.[3]

Which companies are challenging Tenormin, and what is the litigation status?

No active Tenormin litigation is commercially central to the standard atenolol tablet market. The product has been genericized for many years, and ordinary atenolol tablets are supplied by multiple manufacturers.

Relevant litigation risk would arise in three situations:

1. A sponsor launches a newly patented atenolol dosage form.
2. A branded combination product includes atenolol and another protected active ingredient.
3. A manufacturer asserts process or formulation patents against a differentiated dosage form.

For an investor or licensing team, the key diligence point is to avoid treating historical Tenormin patent disputes as evidence of current exclusivity. Current Orange Book listings, FDA approval records, and live federal court dockets control the assessment.[2,4]

How does Tenormin compare with competing beta blockers?

Atenolol competes with metoprolol, bisoprolol, carvedilol, propranolol, and nebivolol. The excipient opportunity depends on the dosage form and clinical positioning of each competitor.

Drug	Common formulation opportunity	Competitive consideration
Atenolol	Low-cost tablet, liquid, orally disintegrating tablet	Mature generic market and renal dosing
Metoprolol	Extended-release matrix systems	Stronger formulation differentiation
Bisoprolol	Immediate-release tablet	Generic price competition
Carvedilol	Immediate- and extended-release products	Broader cardiovascular positioning
Propranolol	Tablets, capsules, liquids	Pediatric and flexible-dose demand
Nebivolol	Specialty generic and branded positioning	Higher differentiation potential

Atenolol’s advantage is formulation simplicity and low active-ingredient cost. Its disadvantage is limited pricing power and strong generic substitution. A differentiated product must solve a practical administration problem rather than compete solely on tablet cost.

What FDA regulatory pathway applies to new atenolol products?

A conventional atenolol tablet can generally be pursued through an ANDA referencing the applicable atenolol reference product. A new dosage form, strength, route, or formulation may require a different pathway depending on the extent of change and whether the product can rely on an existing reference product.

Key regulatory issues include:

• Pharmaceutical equivalence.
• Bioequivalence and comparative dissolution.
• Strength proportionality.
• Tablet scoring and dose uniformity.
• Excipients appropriate for oral administration.
• Stability under ICH conditions.
• Impurity and degradation-product control.
• Container-closure protection from moisture.
• Labeling for renal impairment.
• Pediatric-use considerations for liquids or dispersible forms.

For a new liquid or orally disintegrating product, the sponsor should expect more extensive formulation and usability work than for a direct-compression generic tablet. FDA’s product-specific guidance and current ANDA requirements should govern the development plan.[3,5]

What commercial opportunities exist for Tenormin excipients?

The commercial opportunity is concentrated in niche dosage forms and procurement differentiation.

Hospital and long-term-care channels

Hospitals and long-term-care facilities may value:

• Unit-dose packaging.
• Tube-compatible administration.
• Easy-to-swallow tablets.
• Reduced tablet breakage.
• Reliable supply.
• Fewer excipient allergens or animal-derived materials.

Atenolol products with simple administration instructions can reduce medication-handling friction, but procurement contracts will remain price-sensitive.

Pediatric and geriatric markets

Atenolol liquids and orally disintegrating products could address patients who cannot reliably swallow conventional tablets. The opportunity is strongest where commercially available liquid alternatives are limited or where pharmacies depend on compounding.

Global markets

Excipient preferences vary by jurisdiction. Gelatin, colorants, sodium-containing ingredients, sugar, and animal-derived materials can affect registration, labeling, religious acceptability, and tender eligibility. A modular formulation platform that supports gelatin-free, colorant-free, and lactose-free versions can reduce regional complexity.

Contract manufacturing and private label

Because the active ingredient is inexpensive and the dosage form is mature, contract manufacturers can offer private-label atenolol products to hospitals, wholesalers, and regional distributors. The principal competitive levers are:

• Low minimum order quantities.
• Multiple strengths.
• Reliable supply.
• Flexible packaging.
• Alternate excipient declarations.
• Rapid regulatory support for local markets.

What is the revenue exposure for a Tenormin excipient strategy?

Public financial reporting generally does not isolate Tenormin revenue from broader cardiovascular portfolios or generic atenolol sales. The legacy brand is unlikely to support material premium pricing without a differentiated dosage form, a protected combination product, or a specialized distribution arrangement.

Revenue potential is therefore better assessed through product economics:

Model	Margin outlook	Principal driver
Standard generic tablet	Low	Volume and manufacturing cost
Hospital unit-dose product	Low to moderate	Contract access and packaging
Oral liquid	Moderate	Limited competition and dosing flexibility
Orally disintegrating tablet	Moderate	Patient-use differentiation
Pediatric product	Moderate to high	Specialized supply and formulation
Patented modified-release product	Potentially high	Clinical value and exclusivity
Private-label regional product	Low to moderate	Procurement efficiency

The strongest investment case is a differentiated formulation with modest development cost, a clear patient-use benefit, and protection through formulation patents, trade secrets, regulatory complexity, or commercial contracts.

Key Takeaways

• Tenormin contains atenolol and is available historically in 25 mg, 50 mg, and 100 mg immediate-release tablets.
• Its original patent and exclusivity position has expired; standard atenolol tablets face high generic competition.
• The reference excipient platform includes conventional diluents, binders, lubricants, wetting agents, and superdisintegrants.
• The most credible opportunities are orally disintegrating tablets, oral liquids, scored tablets, tube-compatible products, and gelatin-free formulations.
• A new formulation patent must rely on defined technical features and performance data, not routine excipient substitution.
• Atenolol’s renal elimination makes dose flexibility and administration accuracy commercially relevant.
• Standard tablets offer low-margin volume economics. Liquid, pediatric, geriatric, and specialty-care products offer better differentiation.
• Current FDA Orange Book records, approved labeling, and federal litigation dockets should control any live patent or launch assessment.

FAQs

Can atenolol tablets be reformulated without changing the active ingredient?

Yes. A sponsor can change excipients, compression processes, coating systems, or dosage-form design, but the resulting product must satisfy applicable FDA quality and bioequivalence requirements.

Is a lactose-free Tenormin generic commercially viable?

It can be viable as a procurement and patient-preference product, but lactose-free positioning alone is unlikely to support significant pricing power in the US without broader differentiation.

Can an atenolol oral solution obtain market exclusivity?

A new oral solution may obtain limited protection through formulation patents, regulatory exclusivity where applicable, trade secrets, and commercial contracts. The active ingredient itself does not provide new chemical entity exclusivity.

Does atenolol require a modified-release formulation to be competitive?

No. A modified-release product could be differentiated, but a liquid, orally disintegrating tablet, or tube-compatible product may offer a lower-cost development path with clearer administration benefits.

What is the main manufacturing barrier for atenolol tablets?

The main barriers are process consistency, dissolution control, content uniformity, moisture stability, and reliable low-cost production. The active ingredient and conventional excipients do not create a significant proprietary manufacturing barrier.

References

1. AstraZeneca. (n.d.). Tenormin (atenolol) tablets: US prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application. FDA.

4. U.S. Courts. (2025). PACER case locator and federal civil litigation records. Administrative Office of the U.S. Courts.

5. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. FDA.